|
IMPACT Therapeutics is set to receive an upfront payment, near-term regulatory milestones, and commercial milestone payments for sales.
|
 |
|
The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.
|
|
|
Experts say wider patient access to CGTs hinges on further infrastructure developments and the movement of therapies into the community setting.
|
|
|
Sublingual semaglutide, which does not hold marketing authorisation, is touted to minimise gastric issues.
|
|
|
J&J strikes this deal with Sail as the in vivo CAR-T space becomes increasingly crowded.
|
|
